Allogene Therapeutics joint Schedule 13G/A discloses that Citadel-related entities and Kenneth Griffin report shared beneficial ownership positions in the issuer's common stock. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each report 5,795,242 shares (2.4%). Citadel Securities LLC reports 614,069 shares (0.3%). Citadel Securities Group LP and Citadel Securities GP LLC each report 1,059,878 shares (0.4%). Kenneth Griffin is reported as beneficially owning 6,855,120 shares (2.8%). The filing cites 243,777,920 Shares outstanding as of March 10, 2026 per the issuer's Form 10-K.
Positive
None.
Negative
None.
Insights
Joint disclosure clarifies shared dispositive authority across Citadel entities.
The statement lists specific shared voting and shared dispositive power figures for each reporting person, tying those counts to the issuer's March 10, 2026 outstanding share base of 243,777,920 shares. The filing emphasizes attribution through fund and affiliate structure rather than sole individual ownership.
Watch for subsequent amendments or Form 4s that would show trading direction; this Schedule 13G/A documents passive/beneficial positions and entity relationships disclosed in the filing.
The filing follows Section 13 reporting conventions and notes shared power among affiliates.
It identifies the reporting group (Citadel Advisors, CAH, CGP, Citadel Securities, CALC4, CSGP and Kenneth Griffin) and provides exact share counts and percentages, including a citation to the issuer's Form 10-K for the outstanding share figure.
Filing signatory notes a power of attorney for Mr. Griffin; investors seeking change-in-control signals should rely on future Forms 4 or 13D filings for active trading disclosures.
Key Figures
Shares outstanding:243,777,920 sharesCitadel Advisors holdings:5,795,242 sharesCitadel Securities holdings:614,069 shares+2 more
5 metrics
Shares outstanding243,777,920 sharesas of March 10, 2026 (cited from issuer's Form 10-K)
Citadel Securities holdings614,069 sharesreported for Citadel Securities LLC
Citadel Securities Group holdings1,059,878 sharesreported for Citadel Securities Group LP / CSGP
Kenneth Griffin holdings6,855,120 sharesreported beneficial ownership for Mr. Griffin
Key Terms
Schedule 13G/A, Beneficial ownership, Shared dispositive power, Power of attorney
4 terms
Schedule 13G/Aregulatory
"This is being jointly filed by Citadel Advisors LLC... (first paragraph)"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownershipregulatory
"Ownership (a) | Amount beneficially owned: 1. Each of Citadel Advisors LLC... (Item 4)"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared dispositive powerfinancial
"Shared Dispositive Power 5,795,242.00 (table rows for Citadel entities)"
Power of attorneylegal
"Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney..."
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Allogene Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share (the "Shares")
(Title of Class of Securities)
019770106
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Citadel Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,795,242.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,795,242.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,795,242.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
IA, HC, OO
Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 243,777,920 Shares outstanding as of March 10, 2026 (according to the issuer's Form 10-K as filed with the Securities and Exchange Commission on March 12, 2026).
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Citadel Advisors Holdings LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,795,242.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,795,242.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,795,242.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
HC, PN
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Citadel GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,795,242.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,795,242.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,795,242.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Citadel Securities LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
614,069.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
614,069.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
614,069.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
BD, OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Citadel Securities Group LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,059,878.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,059,878.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,059,878.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.4 %
12
Type of Reporting Person (See Instructions)
HC, PN
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Citadel Securities GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,059,878.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,059,878.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,059,878.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.4 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Kenneth Griffin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,855,120.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,855,120.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,855,120.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.8 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Allogene Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
210 East Grand Avenue, South San Francisco, CA, 94080
Item 2.
(a)
Name of person filing:
This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), Citadel Securities, and CRBU Holdings LLC, a Delaware limited liability company ("CRBH"). Such owned Shares may include other instruments exercisable for or convertible into Shares.
Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities and CRBH. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
(b)
Address or principal business office or, if none, residence:
The address of each of the Reporting Persons is 830 Brickell Plaza, Miami, Florida 33131.
(c)
Citizenship:
Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share (the "Shares")
(e)
CUSIP No.:
019770106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 5,795,242 Shares.
2. Citadel Securities LLC may be deemed to beneficially own 614,069 Shares.
3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 1,059,878 Shares.
4. Mr. Griffin may be deemed to beneficially own 6,855,120 Shares.
(b)
Percent of class:
1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 2.4% of the Shares outstanding.
2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.3% of the Shares outstanding.
3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding.
4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 2.8% of the Shares outstanding.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0
2. Citadel Securities LLC: 0
3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0
4. Mr. Griffin: 0
(ii) Shared power to vote or to direct the vote:
1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 5,795,242
2. Citadel Securities LLC: 614,069
3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 1,059,878
4. Mr. Griffin: 6,855,120
(iii) Sole power to dispose or to direct the disposition of:
1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0
2. Citadel Securities LLC: 0
3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0
4. Mr. Griffin: 0
(iv) Shared power to dispose or to direct the disposition of:
1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 5,795,242
2. Citadel Securities LLC: 614,069
3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 1,059,878
4. Mr. Griffin: 6,855,120
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Citadel Advisors LLC
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, Authorized Signatory
Date:
05/15/2026
Citadel Advisors Holdings LP
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, Authorized Signatory
Date:
05/15/2026
Citadel GP LLC
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, Authorized Signatory
Date:
05/15/2026
Citadel Securities LLC
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, Authorized Signatory
Date:
05/15/2026
Citadel Securities Group LP
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, Authorized Signatory
Date:
05/15/2026
Citadel Securities GP LLC
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, Authorized Signatory
Date:
05/15/2026
Kenneth Griffin
Signature:
/s/ Seth Levy
Name/Title:
Seth Levy, attorney-in-fact*
Date:
05/15/2026
Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
What does the Allogene (ALLO) Schedule 13G/A disclose?
It lists Citadel-related entities and Kenneth Griffin as beneficial owners. The filing provides specific share counts and percentages tied to 243,777,920 outstanding shares as of March 10, 2026.
How many shares does Citadel Advisors report owning in ALLO?
Citadel Advisors LLC, CAH and CGP each report 5,795,242 shares, representing 2.4% of the shares outstanding as stated in the filing on March 10, 2026.
What stake does Kenneth Griffin report in Allogene (ALLO)?
Kenneth Griffin is reported as beneficially owning 6,855,120 shares, equal to 2.8% of the outstanding shares based on the filing's cited 243,777,920 share base.
Does this filing indicate active trading or control transactions?
No specific trades or control transfers are disclosed. The Schedule 13G/A reports beneficial ownership and shared dispositive power; it does not state purchases, sales, or acquisition agreements.
Where do the ownership percentages come from in the filing?
Percentages are calculated using the issuer's stated outstanding share count of 243,777,920 shares as of March 10, 2026, cited from the issuer's Form 10-K in the filing.
